PPT-The concept of Diabetes & CV risk:

A lifetime risk challenge Vascular function as an early sign of trouble How can the inhibition of cholesterol absorption reduce the atherogenic load of intestinal lipoproteins Prof Frank Visseren . Prof. John Betteridge, MD. University College London. London, United Kingdom. Cardio. Diabetes . Master. . Class. Asian. . chapter. January. 28-30 2011, . Shanghai. Slide lecture prepared and held by:. A lifetime risk challenge. Priorities in the management . of . type 2 diabetes:. Past, present and future. Sir George Alberti, MD. Diabetes UK Chairman. Newcastle. , United Kingdom. Cardio. Diabetes . Chapter 5. Thomas . Ransom, Ronald Goldenberg, Amanda . Mikalachki. , Ally . PH . Prebtani. , . Zubin. . Punthakee. Canadian Diabetes Association 2013 Clinical Practice Guidelines. Key Points. At this time, there are no safe and effective strategies to prevent T1DM. Applying evidence based medicine to clinical care. Cardiovascular disease is the biggest killer in UK. Number. of . deaths. (000’s). 124,037. 60,666. 18,165. 33,634. 16,216. 12,762. 103,431. 19,996. A lifetime risk challenge. Priorities in the management . of . type 2 diabetes:. Past, present and future. Sir George Alberti, MD. Diabetes UK Chairman. Newcastle. , United Kingdom. Cardio. Diabetes . Years from . diagnosis. 0. 5. -10. -5. 10. 15. Pre-diabetes. Onset. Diagnosis. Insulin secretion. Insulin “efficiency”. Ramlo-Halsted BA, Edelman SV. . Prim Care. . 1999;26:771-789 Nathan DM. . N Engl J Med. . 1. Obesity. Management of Common Comorbidities in Diabetes. 2. 3. 4. More Than Two Thirds of US Adults Are Overweight or Obese. 5. *2014 rate of overweight not reported in . Flegal. et al 2016; 2012 rate carried over based on historic stability of overweight prevalence.. Figure 1 T1D Incidence Rates Worldwide 0510152025303540FINSARSWENORUS-WIUS-PAITAISRJAPCHIare being diagnosed with the T1D around the world each year Although the peak age at onset is at puberty T1D Gynecologist & obstetrician . 5-7% . of . pregnancies. 90% GDM & 10% diabetes type 1&2 . . Insulin . resistance in pregnancy in favor of : . placental . secretion of . GH,CRH,PL,progestron. MAHTAB NIROOMAND M.D.. Assistant professor of Endocrinology. SBUMS. Tehran 1391/11/19. . Out-line . Pathophysiology. and types of dyslipidemia in diabetic patients. Benefits of lipid- lowering therapy. Prof Kausik Ray, . BSc (. hons. ), . MBChB. , MRCP, MD, MPhil (. Cantab. ), FACC, FESC, FAHA. Professor of Cardiovascular Disease Prevention. St Georges University of London. Honorary Consultant Cardiologist St Georges Hospital. David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . the . time for personalized treatments. . Woolf SH, et al. . BMJ . 1999;318:527–30 . Maddaloni. E, . Pozzilli. P. . Treatment strategies – Diabetes 2014; . 6:45-49. Type 2 diabetes is a . complex disease . Nathan D. Wong, PhD, FACC, FAHA, FNLA, FASPC. Professor and Director. Heart Disease Prevention Program. Division of Cardiology. University of California, Irvine. Editorial Lead, ACC Diabetes and Cardiometabolic Clinical Topic Collection.